背景介绍 This antibody binds and blocks the activation of the PD-1 receptor. The antibody is humanized, containing a human IgG4 Fc region with an engineered hinge region mutation (S228P) designed to prevent the exchange of IgG4 molecules. This antibody is equivalent to Nivolumab, which has been approved by the FDA for the treatment of melanoma and metastatic squamous non-small cell lung cancer. 产品介绍 Humanized recombinant anti-PD-1 (IgG4) antibody with S228P mutation, expressed in HEK293 cells. This antibody has not been tested with other species.